Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society - 1 Mar 2021

Moheet Amir, Beisang Daniel, Zhang Lin, Sagel Scott D, VanDalfsen Jill M, Heltshe Sonya L, Frederick Carla, Mann Michelle, Antos Nicholas, Billings Joanne, Rowe Steven M, Moran Antoinette

Abstract excerpt

BACKGROUND: Glucose tolerance abnormalities including cystic fibrosis related diabetes (CFRD) are common in patients with cystic fibrosis (CF). The underlying pathophysiology is not fully understood. Emerging evidence suggests that CFTR dysfunction may directly or indirectly impact β-cell function, offering the potential for improvement with CFTR modulator therapy. In small pilot studies, treatment with ivacaftor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Aminopyridines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzodioxoles

Share to Chloride Channel Agonists

Share to Drug Combinations

Share to Glucose Tolerance Test

Share to Insulin Secretion

Share to Quinolones

Source

Open in PubMed Open full text

Identifiers

PMID: 32917547
DOI: 10.1016/j.jcf.2020.09.001
PMCID: PMC7937760

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients.PMID 32917547Read ↗

Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion.Semantic proximity Read ↗

Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study.Semantic proximity Read ↗

Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor.Semantic proximity Read ↗

CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation.Semantic proximity Read ↗

Changes in glucose tolerance in people with cystic fibrosis after initiation of first-generation CFTR modulator treatment.Semantic proximity Read ↗

Improved glucose tolerance after initiation of Elexacaftor / Tezacaftor / Ivacaftor in adults with cystic fibrosis.Semantic proximity Read ↗

Improvements in Glucose Regulation in Children and Young People with Cystic Fibrosis-Related Diabetes following Initiation of Elexacaftor/Tezacaftor/Ivacaftor.Semantic proximity Read ↗

Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes.Semantic proximity Read ↗

Managing diabetes in cystic fibrosis.Semantic proximity Read ↗

Insulin-secretion abnormalities and clinical deterioration related to impaired glucose tolerance in cystic fibrosis.Semantic proximity Read ↗

Decline in HbA1c during the first year of elexacaftor/tezacaftor/ivacaftor treatment in the Danish cystic fibrosis cohort: Short title: Decline in HbA1c after elexacaftor/tezacaftor/ivacaftor treatment.Semantic proximity Read ↗

Evaluation of glucose tolerance and insulin secretion in cystic fibrosis patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.